Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06364033
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-09
First Post:
2024-04-09
Brief Title:
Biological and Clinical Efficacy of Shingrix in Patients With CLL
Sponsor:
Gruppo Italiano Malattie EMatologiche dellAdulto
Organization:
Gruppo Italiano Malattie EMatologiche dellAdulto
Study Overview
Official Title:
Biological and Clinical Efficacy of Recombinant Zoster Vaccine Shingrix in Patients With Chronic Lymphocytic Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a biological study Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study According to AIFA indication the two doses of vaccine will be administered 4-8 weeks apart Blood samples will be collected prior to the first vaccine dose ie within the time frame of 3 months prior to the first dose and 1 6 12 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix
Detailed Description:
This is a multi-centre prospective study performed on biological samples only Patients who are eligible to receive Shingrix through the Italian National Health System will be invited to participate in the study
According to AIFA indication the two doses of vaccine will be administered 4-8 weeks apart
Blood samples will be collected prior to the first vaccine dose ie within the time frame of 3 months prior to the first dose and 1 6 12 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix All protocol procedures including clinical assessment and blood draws will be performed during regular follow-up visits according to clinical practice No additional invasivedangerouspainful procedures will be required by the study
According to AIFA indication the two doses of vaccine will be administered 4-8 weeks apart
Blood samples will be collected prior to the first vaccine dose ie within the time frame of 3 months prior to the first dose and 1 6 12 24 and 36 months after the second vaccine dose to evaluate the serological response of Shingrix All protocol procedures including clinical assessment and blood draws will be performed during regular follow-up visits according to clinical practice No additional invasivedangerouspainful procedures will be required by the study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None